The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...
GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...
Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...
First orphan designation ever granted to a condensate-modulating therapeuticBuilds on recent IND opening for DPTX3186, a ...
Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer ...
US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...
The first-in-class FGFR2b antibody bemarituzumab extends overall survival in patients with advanced gastric cancer, but the ...
MedPage Today on MSN
Cancer Drug Pulled From Market Regains FDA Approval
It's been a roller coaster ride for the drug ever since it was granted accelerated approval in 2020 for the treatment of ...
An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...
John Middleton of North Carolina has been told without a liver transplant, he likely has about 18 months to live. His doctor ...
Money Talks News on MSN
The Affordable Wonder Drug That Could Change Cancer Treatment
Trump Warns of Threat to Social Security, Medicare Exclusive: Three-star general pushed out amid tensions with Hegseth GM to ...
Many cancer survivors live with the worry that their cancer might come back. This "recurrence" occurs when cancer cells hide somewhere in the body—like in the bone marrow—and start growing again, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback